Risultati per: Nuovi trattamenti nei linfomi non Hodgkin a cellule B

Condotto dall’Enea. Biomolecole ne inibiscono la proliferazione

Dal sistema immunitaria, per contrastare metastasi e recidive

Modificate geneticamente abbattono i tassi di recidività

This cohort study examines the role of comprehensive bridging radiotherapy in the setting of chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.

All’Humanitas. Con nuove terapie speranze di cura per il 70% dei pazienti

Promo centro in Italia a praticarlo, è il terzo nel mondo

Circulation, Volume 148, Issue Suppl_1, Page A13023-A13023, November 6, 2023. Background:Non-Hodgkin lymphoma (NHL) survivors are at increased risks of cardiovascular disease related death (CVD) compared to the general population.Objective:This study sought to determine the longitudinal trends in mortality attributed to CVD with comorbid NHL by race, sex, and geographic location.Methods:We queried the Centers for Disease Control and Prevention’s Wide-Ranging Online Data for Epidemiologic Research database among patients aged 18 and above from 1999 to 2020. Patients were identified when the primary causes of death were ischemic heart diseases (ICD 10 I20-I25), cerebrovascular diseases (I60-I69), or hypertensive disease (I10-I15), and NHL (C82-C85) was a contributing cause of death. We calculated age-adjusted mortality rates (AAMRs) per 1,000,000 individuals and determined the trends over time by estimating the annual percent change using the Joinpoint regression program.Results:In the 22-year study period, a total of 22,778 CVD with comorbid NHL were identified. Overall, there was a significant decrease in annual trends for the AAMRs of CVD from 6.91 per 1,000,000 individuals in 1999 to 4.12 per 1,000,000 individuals in 2020 (p

Fondazione Tettamanti: ‘Più semplice e meno costoso delle Car-T’

Possibile ruolo contro Alzheimer e Parkinson

Studio, sono meno capaci di combattere il virus